Welcome to our dedicated page for Uniqure SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The uniQure N.V. (QURE) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, uniQure files current reports on Form 8‑K, annual reports on Form 10‑K, and quarterly reports on Form 10‑Q that describe its gene therapy business, clinical programs, financial condition, and material agreements. These filings document the company’s work in hemophilia B, Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe conditions.
For uniQure, Form 8‑K filings are particularly important. They include clinical and regulatory updates on AMT‑130 for Huntington’s disease, such as topline Phase I/II data, details of pivotal trial design, and feedback from pre‑Biologics License Application meetings with the U.S. Food and Drug Administration. Other 8‑K reports describe public offerings of ordinary shares and pre‑funded warrants, amendments to senior secured term loan facilities with Hercules Capital, and the establishment of at‑the‑market equity programs. Filings also reference the company’s role in the multi‑year clinical development of a gene therapy for hemophilia B and its licensing arrangements with CSL.
On this page, investors can review uniQure’s SEC documents to understand how it reports results of operations, research and development spending, direct financial obligations, and other events that may affect QURE stock. Stock Titan enhances access to these filings with AI‑powered summaries that highlight key points from lengthy reports, helping readers quickly identify major clinical milestones, regulatory decisions, financing terms, and risk disclosures. Real‑time updates from EDGAR, along with structured access to items such as 8‑K current reports and other registered offerings, support deeper analysis of uniQure’s evolving gene therapy portfolio and capital structure.
uniQure N.V. convenes its 2026 Annual General Meeting on June 10, 2026 to vote on routine Dutch-law items and governance actions, including adoption of the 2025 Dutch statutory annual accounts, discharge of the Board, reappointments of three non-executive directors, authorizations to issue up to 12,400,000 ordinary shares (approx. 19.7%), authority to exclude or limit pre-emptive rights, an 18‑month share repurchase authorization up to 10% of issued capital, appointment of KPMG as auditor, and an amendment to the 2014 Share Incentive Plan increasing the reserve to 11,040,279 shares. The record date is May 13, 2026, and approximately 63,065,985 Ordinary Shares were expected outstanding as of that date.
uniQure N.V. reported that Chief Customer & Strategy Officer Kylie O'Keefe received new equity awards. On March 4, 2026, she was granted stock options for 31,900 shares at an exercise price of $0.00 per share and 19,800 ordinary shares as restricted share units.
The restricted share units vest in three equal annual installments of one-third each, starting on the first anniversary of the grant date, subject to her continued relationship with the company. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested, also contingent on continued service.
uniQure N.V. executive Kylie O'Keefe filed an initial ownership report, showing existing equity awards in the company. The filing lists 180,000 stock options and 105,000 Ordinary Shares held directly as of the reporting date. Footnotes explain that these positions arise from prior equity grants that vest over time.
Restricted share units granted on June 11, 2025 convert into Ordinary Shares in three equal annual installments, subject to continued service. A stock option granted the same day vests over four years, with 25% vesting after one year and the remainder vesting quarterly until June 11, 2029, also contingent on continued service.
uniQure N.V. CEO and managing director Matthew C. Kapusta reported new equity compensation grants and a small related share sale. He was granted stock options for 113,800 shares at an exercise price of $0.00 per share and 70,600 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments beginning on the first anniversary of the grant date, subject to his continued service. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested. In a separate transaction, 14,581 ordinary shares were sold at a weighted average price of $9.06 per share, within a range of $9.00 to $9.22, solely to cover estimated withholding taxes under automatic sale instructions, and were not a discretionary trade.
uniQure N.V.’s Chief Medical Officer Walid Abi-Saab reported new equity awards and a small automatic share sale. He was granted stock options for 67,200 shares at an exercise price of $0.00 and 41,700 restricted share units, each representing the right to receive one ordinary share.
The restricted share units vest in three equal annual installments starting one year after the grant date, subject to continued service. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested, also contingent on continued service.
Upon vesting of restricted share units, 808 ordinary shares were sold at a weighted average price of $9.06, within a $9.00–$9.22 range, solely to cover estimated withholding taxes under automatic sale instructions, not as a discretionary trade. After these transactions, he directly owned 189,669 ordinary shares.
uniQure N.V.’s Chief Legal Officer, Jeannette Potts, reported a mix of equity awards and an automatic share sale. She received a grant of 57,200 stock options with an exercise price of $0.00 per share and 35,400 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments starting one year after the grant date, contingent on her continued service. The stock options vest 25% after one year and 6.25% quarterly thereafter. In connection with vesting, 3,412 ordinary shares were sold at a weighted average price of $9.06, within a $9.00–$9.22 range, solely to cover estimated withholding taxes under automatic sale instructions, and were not a discretionary trade.
uniQure N.V.’s Chief Financial Officer, Christian Klemt, reported a mix of equity awards and an automatic tax-related sale. On March 4, 2026, he received a stock option for 63,900 shares at an exercise price of $0.00 and a grant of 39,600 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments beginning on the first anniversary of grant, subject to his continued relationship with the company. On the same date, 12,000 ordinary shares were sold at a weighted average price of $9.06 per share, within a price range of $9.00 to $9.22, solely to cover estimated withholding taxes under automatic sale instructions, not as a discretionary trade.
uniQure NV reports a proposed sale of ordinary shares and recent insider dispositions. The filing notifies a proposed sale of 12,000 ordinary shares through Citigroup Global Markets on 03/04/2026. The notice also lists 24,333 restricted stock units vesting on 03/04/2026 as compensation. Recent reported dispositions by Christian Klemt total 18, + (6,217 and 12,832) ordinary shares sold in February–March 2026 with reported proceeds shown in the excerpt.
uniQure NV submitted a Form 144 disclosing the proposed sale of 33,000 ordinary shares underlying restricted stock units that vest on 03/04/2026. The filing also reports prior open-market sales by Matthew Kapusta of 12,378 shares on 02/25/2026 ($295,306.90) and 34,437 shares on 03/02/2026 ($342,586.16).